エストラムスチン併用ドセタキセル化学療法により長期の病勢安定が得られた去勢抵抗性前立腺癌の1例

HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Long-Term Disease Stabilization by Docetaxel Plus Estramustine for Castration-Resistant Prostate Cancer : Report of a Case
  • エストラムスチン ヘイヨウ ドセタキセル カガク リョウホウ ニ ヨリ チョウキ ノ ビョウセイ アンテイ ガ エラレタ キョセイ テイコウセイ ゼンリツセンガン ノ 1レイ

この論文をさがす

抄録

Chemotherapy with docetaxcel (DTX) plus estramustine (EMP) for castration-resistant prostate cancer (CRPC) was started 30 months after the patient, a 65-year-old man, was diagnosed as having advanced prostate cancer cT3aN1M1 (OSS) with an initial PSA of 490 ng/ml. Prostate biopsy specimens revealed moderately differentiated adenocarcinoma, Gleason’s sum 4＋5. He was treated with DTX 30 mg/m2 on day 2 and oral EMP 560 mg/day days 1-3 weekly for 3 out of 4 weeks. PSA at start of DTX plus EMP was 81.7 ng/ml, and that after 59 months was 66.6 ng/ml. No objective change in computed tomography and bone scan were observed. He also had no cancer-related symptoms and activity of daily life was good. Chemotherapy was interrupted twice because of pleural effusion and dyspnea by DTX, at 3 and 4 months, respectively, long-term disease stabilization was obtained by this treatment. Other adverse events including interstitial pneumonia, cardiovascular disorders and myelosuppression were not observed. He was maintained on the same chemotherapy. DTX plus EMP chemotherapy is an effective treatment for CRPC patients. Continuing this therapy it is important to survey and control adverse events caused by DTX and EMP carefully.

収録刊行物

  • 泌尿器科紀要

    泌尿器科紀要 57 (4), 203-207, 2011-04

    泌尿器科紀要刊行会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ